Bone Effects of Rosiglitazone in HIV-Infected Patients With Lipoatrophy

REFERENCES

• Brown TT, Qaqish RB. Antiretroviral therapy and the preva-lence of osteopenia and osteoporosis: a meta-analytic review [see comment]. AIDS. 2006;20(17):2165–2174.
   PubMed Web of Science ®Google Scholar
• Dao C, Young B, Buchacz K, Baker R, Brooks J; HOPS. Higher and increasing rates of fracture among HIV-infected persons in the HIV outpatient study (HOPS) compared to the general US population, 1994 to 2008. Paper presented at: 17th Conference on Retroviruses and Opportunistic Infection; 2010; San Francisco, CA.
   Google Scholar
• Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture preva-lence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metabol. 2008;93(9):3499–3504.
   PubMed Web of Science ®Google Scholar
• Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS. 2009;27(7):817–824.
   Web of Science ®Google Scholar
• Aukrust P, Haug CJ, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normali-zation of the bone-remodeling process during highly active antiretroviral therapy. JClin EndocrinolMetaboL 1999;84(1): 145–150.
   PubMed Web of Science ®Google Scholar
• Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36(4):482–490.
   PubMed Web of Science ®Google Scholar
• Moore AL, Vashisht A, Sabin CA, et al. Reduced bone mineral density in HIV-positive individuals. AIDS. 200115(13):1731–1733.
   Google Scholar
• Fausto A, Bongiovanni M, Cicconi P, et al. Potential predic-tive factors of osteoporosis in HIV-positive subjects. Bone. 2006;38(6):893–897.
   PubMed Web of Science ®Google Scholar
• Bongiovanni M, Fausto A, Cicconi P, et al. Osteoporosis in HIV-infected subjects: a combined effect of highly active antiretroviral therapy and HIV itself? J Acquir Immune Defic Syndr 2005;40(4):503–504.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Kitch D, Daar ES, et al. Bone mineral den-sity and fractures in antiretroviral-naive persons random-ized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011203(12):1791–1801.
   Google Scholar
• Kwan Tat S, Padrines M, Theoleyre S, Heymann D, Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 2004;15(1):49–60.
   PubMed Web of Science ®Google Scholar
• Aukrust P, Muller F, Lien E, et al. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure. J Infect Dis. 1999;179(1): 74–82.
   PubMed Web of Science ®Google Scholar
• Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009;51(5): 554–561.
   PubMed Web of Science ®Google Scholar
• Moyle G, Givens N, Pearce H, Compston J; ASSERT. Effect of ART on bone turnover markers and bone den-sity in HIV infected patients. Paper presented at: 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV; 2009; Philadelphia, PA.
   Google Scholar
• Fakruddin JM, Laurence J. HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol. 2005;150(1):67–78.
   PubMed Web of Science ®Google Scholar
• Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem. 2003;278(48):48251–48258.
   PubMed Web of Science ®Google Scholar
• Seminari E, Castagna A, Soldarini A, et al. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med. 2005;6(3):145–150.
   PubMed Web of Science ®Google Scholar
• Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Vigano A. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS. 2001;15(14):1823–1829.
   PubMed Web of Science ®Google Scholar
• Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354(9184)1112–1115.
   Web of Science ®Google Scholar
• Mallon PW, Sedwell R, Rogers G, et al. Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction. J Infect Dis. 2008;198(12):1794–1803.
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11)1106–1118.
   Google Scholar
• Tungsiripat M, Bejjani DE, Rizk N, et al. Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens. AIDS. 2010;24(9)1291–1298.
   Web of Science ®Google Scholar
• Raboud JM, Diong C, Carr A, et al. A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials. 2010;11(1):39–50.
   PubMed Web of Science ®Google Scholar
• Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology. 2005;146(3):1226–1235.
   PubMed Web of Science ®Google Scholar
• Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective per-oxisomeproliferator-activated receptor-gamma 2 ligandson adipocyte versus osteoblast differentiation. Endocrinology. 2002;143(6):2376–2384.
   PubMed Web of Science ®Google Scholar
• Tornvig L, Mosekilde LI, Justesen J, Falk E, Kassem M. Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int. 2001;69(1):46–50.
   PubMed Web of Science ®Google Scholar
• Murphy CE, Rodgers PT. Effects of thiazolidinedio-nes on bone loss and fracture. Ann Pharmacother. 2007;41(12):2014–2018.
   PubMed Web of Science ®Google Scholar
• Douglas IJ, Evans SJ, Pocock S, Smeeth L. The risk of frac-tures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med. 2009;6(9):e1000154.
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidin-edione use and bone loss in older diabetic adults. J Clin Endocrinol MetaboL 2006;91(9):3349–3354.
   PubMed Web of Science ®Google Scholar
• Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168(8):820–825.
   PubMed Web of Science ®Google Scholar
• Ryan KE, McCance DR, Powell L, McMahon R, Trimble ER. Fenofibrate and pioglitazone improve endothelial func-tion and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis. 2007;194(2):e123–130.
   PubMed Web of Science ®Google Scholar
• Koufany M, Moulin D, Bianchi A, et al. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis. Arthritis Res Ther 2008;10(1):R6.
   PubMed Web of Science ®Google Scholar
• Hassumi MY, Silva-Filho VJ, Campos-Junior JC, et al. PPAR-gamma agonist rosiglitazone prevents inflammatory periodontal bone loss by inhibiting osteoclastogenesis. Int Immunopharmacol. 2009;9(10):1150–1158.
   PubMed Web of Science ®Google Scholar
• Jiang M, Lu S, Wu L, Liu J, Cheng P, Ding GX. [Effect of pioglitazone on receptor activator of nuclear factor-kappa B expression in osteoclast from RAW264.7 cells]. Zhong-hua Yi Xue Za Zhi. 2010;90(32):2282–2285.
   PubMedGoogle Scholar
• An JJ, Han DH, Kim DM, et al. Expression and regula-tion of osteoprotegerin in adipose tissue. Yonsei Med J. 2007;48(5):765–772.
   PubMed Web of Science ®Google Scholar
• Schwab AM, Granholm S, Persson E, Wilkes B, Lerner UH, Conaway HH. Stimulation of resorption in cultured mouse calvarial bones by thiazolidinediones. Endocrinology. 2005;146(10):4349–4361.
   PubMed Web of Science ®Google Scholar
• Yarasheski KE, Cade WT, Overton ET, et al. Exercise train-ing augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity. Am J Physiol Endocrinol Metabol. 2011;300(1):E243–251.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabe-tologia. 1985;28(7):412–419.
   PubMed Web of Science ®Google Scholar
• Tungsiripat M, El-Bejjani D, Rizk N, et al. Carotid intima media thickness, inflammatory markers, and endothe-lial activation markers in HIV Patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo. AIDS Res Human Retroviruses. 2011;27(3): 295–302.
   PubMed Web of Science ®Google Scholar
• Grey A, Bolland M, Gamble G, et al. The peroxisome pro-liferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metabol. 2007;92(4):1305–1310.
   PubMed Web of Science ®Google Scholar
• Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care. 2007;30(6):1574–1576.
   PubMed Web of Science ®Google Scholar
• Eastell R, Hannon RA. Biomarkers of bone health and osteoporosis risk. Proc Nutr Soc. 2008;67(2):157–162.
   PubMed Web of Science ®Google Scholar
• Kushida K, Takahashi M, Kawana K, Inoue T. Comparison of markers for bone formation and resorption in premeno-pausal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metabol. 1995;80(8):2447–2450.
   PubMed Web of Science ®Google Scholar
• Seibel MJ, Gartenberg F, Silverberg SJ, Ratcliffe A, Robins SP, Bilezikian JP. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Clin Endocrinol Metabol. 1992;74(3):481–486.
   PubMed Web of Science ®Google Scholar
• Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res. 2005;20(1):141–151.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Kendall MA, Tebas P, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS. 2007;21(18):2473–2482.
   PubMed Web of Science ®Google Scholar
• Lee AJ, Hodges S, Eastell R. Measurement of osteocalcin. Ann Clin Biochem. 2000;37\(pt 4):432–446.
   PubMed Web of Science ®Google Scholar
• Linkhart SG, Linkhart TA, Taylor AK, Wergedal JE, Bet-tica P, Baylink DJ. Synthetic peptide-based immunoas-say for amino-terminal propeptide of type I procollagen: application for evaluation of bone formation. Clin Chem. 1993;39(11 pt 1):2254–2258.
   PubMed Web of Science ®Google Scholar
• Vasikaran S, Eastell R, Bruyere O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international refer-ence standards. Osteoporosis Int. 2011;22(2):391–420.
   PubMed Web of Science ®Google Scholar
• Berberoglu Z, Gursoy A, Bayraktar N, Yazici AC, Bascil Tutuncu N, Guvener Demirag N. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in post-menopausal diabetic women. J Clin Endocrinol Metabol. 2007;92(9):3523–3530.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Nevitt MC, et al. Bone den-sity at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet. 1993;341 (8837):72–75.
   PubMed Web of Science ®Google Scholar
• Warming L, Hassager C, Christiansen C. Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporosis Int. 2002;13(2):105–112.
   PubMed Web of Science ®Google Scholar
• McComsey G, Kitch D, Daar E, et al. Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase iii trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection. Paper presented at: 17th Conference on retroviruses and Opportunistic Infections; 2010; San Francisco, CA.
   Google Scholar
• Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. Am J Med. 2009;122(7): 599–604.
   PubMed Web of Science ®Google Scholar
• Sambrook P. Tumour necrosis factor blockade and the risk of osteoporosis: back to the future. Arthritis Res Ther 2007;9(4):107.
   PubMed Web of Science ®Google Scholar
• Ross AC, Armentrout R, O'Riordan MA, et al. Endothelial activation markers are linked to HIV status and are inde-pendent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr 2008;49:499–506.
   PubMed Web of Science ®Google Scholar
• Ross AC, Rizk N, O'Riordan MA, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis. 2009;49(7):1119–1127.
   PubMed Web of Science ®Google Scholar
• Aubert RE, Herrera V, Chen W, Haffner SM, Pendergrass M. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metabol. 2010;12 (8):716–721.
   PubMed Web of Science ®Google Scholar